Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial.
Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Park CK, et al. Among authors: yang sh. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. doi: 10.1016/j.cllc.2017.01.002. Epub 2017 Jan 11. Clin Lung Cancer. 2017. PMID: 28185792 Clinical Trial.
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.
Kim T, Jang TW, Choi CM, Kim MH, Lee SY, Park CK, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH. Kim T, et al. Among authors: yang sh. Cancer Med. 2021 Sep;10(17):5809-5822. doi: 10.1002/cam4.4127. Epub 2021 Jul 13. Cancer Med. 2021. PMID: 34258882 Free PMC article.
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.
Lee JH, Kim EY, Park CK, Lee SY, Lee MK, Yoon SH, Lee JE, Lee SH, Kim SJ, Lee SY, Lim JH, Jang TW, Jang SH, Lee KY, Lee SH, Yang SH, Park DW, Park CK, Kang HS, Yeo CD, Choi CM, Lee JC. Lee JH, et al. Among authors: yang sh. Cancer Res Treat. 2023 Jan;55(1):112-122. doi: 10.4143/crt.2022.381. Epub 2022 Jul 19. Cancer Res Treat. 2023. PMID: 36049499 Free PMC article.
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study.
Kim T, Jang TW, Choi CM, Kim MH, Lee SY, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH, Oh HJ. Kim T, et al. Among authors: yang sh. Cancer Res Treat. 2023 Oct;55(4):1152-1170. doi: 10.4143/crt.2023.493. Epub 2023 May 19. Cancer Res Treat. 2023. PMID: 37218139 Free PMC article.
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors.
Kim J, Jang TW, Choi CM, Kim MH, Lee SY, Park CK, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH. Kim J, et al. Among authors: yang sh. Transl Lung Cancer Res. 2023 Jun 30;12(6):1197-1209. doi: 10.21037/tlcr-22-832. Epub 2023 Jun 12. Transl Lung Cancer Res. 2023. PMID: 37425421 Free PMC article.
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data.
Choi J, Choi CM, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park JY, Kim YC, Oh IJ, Jung CY, Lee SH, Yoon SH, Lee SY, Jang TW. Choi J, et al. Among authors: yang sh. Transl Lung Cancer Res. 2023 Nov 30;12(11):2275-2282. doi: 10.21037/tlcr-23-383. Epub 2023 Nov 28. Transl Lung Cancer Res. 2023. PMID: 38090523 Free PMC article.
2,767 results